Approximately 3%–5% of the NSCLC cases harbor an echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement and may respond to targeted therapy [1–5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.